Bristol Competitors

Stocks . Brazil . 
Stock . Bristol Myers Squibb
BMYB34 Stock  BRL 341.70  2.83  0.84%   
Bristol Myers Squibb competes with Energisa, BTG Pactual, Plano Plano, Companhia Habitasul, and Procter Gamble; as well as few others. The company operates under Healthcare sector and is part of Drug Manufacturers - Major industry. Analyzing Bristol Myers competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Bristol Myers to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Bristol Myers Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Bristol Myers competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
336.91338.87340.83
Details
Intrinsic
Valuation
LowRealHigh
304.98380.71382.67
Details
Naive
Forecast
LowNextHigh
344.14346.10348.06
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
282.44316.61350.77
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bristol Myers. Your research has to be compared to or analyzed against Bristol Myers' peers to derive any actionable benefits. When done correctly, Bristol Myers' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Bristol Myers Squibb.

Bristol Myers Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bristol Myers and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Bristol and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bristol Myers Squibb does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
BTLG11
+ 0.9
ENGI11
HBTS5
+ 0.87
ENGI11
HBTS5
+ 0.86
BTLG11
E1RI34
+ 0.8
PLPL3
BEWZ39
+ 0.8
E1RI34
BEWZ39
+ 0.74
PLPL3
  
High negative correlations   
E1RI34
- 0.86
BTLG11
HBTS5
- 0.83
PLPL3
BEWZ39
- 0.81
BTLG11
BEWZ39
- 0.8
HBTS5
PLPL3
- 0.8
BTLG11
E1RI34
- 0.79
HBTS5

Risk-Adjusted Indicators

There is a big difference between Bristol Stock performing well and Bristol Myers Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bristol Myers' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Bristol Myers Competitive Analysis

The better you understand Bristol Myers competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bristol Myers' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bristol Myers' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BMYB34 ENGI11 BTLG11 PLPL3 HBTS5 PGCO34 E1RI34 C1AB34 ATMP3 BEWZ39
 0.84 
 341.70 
Bristol
 2.37 
 41.97 
Energisa
 0.67 
 97.08 
BTG
 1.69 
 13.20 
Plano
 0.00 
 30.90 
Companhia
 2.60 
 73.36 
Procter
 2.48 
 23.16 
Telefonaktiebolaget
 1.73 
 11.73 
Cable
 4.41 
 1.30 
ATMA
 0.29 
 52.20 
Ishares
Market Volatility
(90 Days Market Risk)
Very steady
Out of control
Very steady
Not too volatile
Not too volatile
Very steady
Not too volatile
Not too volatile
Out of control
Very steady
Market Performance
(90 Days Performance)
Solid
Very Weak
Very Weak
Insignificant
Very Weak
OK
OK
Good
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Low
Below Average
Low
Low
Low
Quite High
About Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Under Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Not Rated
Cautious Hold
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Buy
Not Rated
Strong Sell
Current Ratio
3.88
1.65
2.78
5.68
0.51
0.79
N/A
1.86
0.41
N/A
Net Asset
109.31 B
54.77 B
N/A
1.27 B
1.32 B
117.21 B
305.61 B
6.95 B
1.77 B
N/A
Profit Margin
0.14
0.086
18.96
0.0763
0.068
0.18
0.069
0.22
-0.58
N/A
EBITDA
18.54 B
6.46 B
N/A
190.28 M
196.32 M
21.24 B
38.66 B
789.6 M
(21.6 M)
N/A
Operating Margin
0.2
0.21
62.59
0.0975
0.27
0.23
N/A
0.31
-0.37
N/A
Current Valuation
1.04 T
18.78 B
202.43 M
971.73 M
470.48 M
2.06 T
101.24 B
41.25 B
300.54 M
N/A
Price To Book
5.0
N/A
1.08
1.81
0.55
8.36
1.46
2.3
N/A
N/A
Five Year Return
N/A
2.94
N/A
N/A
2.94
N/A
N/A
N/A
N/A
N/A
Retained Earnings
N/A
N/A
N/A
N/A
260 M
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
N/A
N/A
N/A
79 M
N/A
N/A
N/A
N/A
N/A
Beta
0.42
0.66
0.65
-0.66
0.8
0.4
0.27
0.81
0.89
N/A
Number Of Employees
41
17.15 K
N/A
6
12
106 K
105.53 K
3.63 K
15.39 K
N/A
Shares Outstanding
2.13 B
N/A
1.65 M
198.26 M
5.95 M
33.03 B
6.66 B
1.16 B
26.71 M
N/A
Cash Flow From Operations
16.21 B
881.74 M
5.63 M
73.71 M
(80.77 M)
16.72 B
39.06 B
704.34 M
44.98 M
N/A
Annual Yield
0.0312
0.086
N/A
0.0386
0.0384
0.0262
0.0457
0.0136
N/A
N/A
Total Debt
39.6 B
19.31 B
N/A
347.45 M
173.49 M
22.85 B
22.24 B
3.8 B
200.39 M
N/A
Return On Equity
0.18
0.23
1.13
0.29
0.0216
0.32
0.16
0.21
-15.83
N/A
Z Score
12.0
N/A
N/A
2.2
N/A
45.0
2.4
3.6
N/A
N/A
Return On Asset
0.0613
0.0655
2.33
0.0624
0.0204
0.0955
0.0592
0.0472
-0.11
N/A
Book Value Per Share
15.38
5.73
98.81
1.94
54.72
1.31
N/A
325.52
-10.3
N/A
Current Liabilities
N/A
N/A
N/A
N/A
102 M
N/A
N/A
N/A
N/A
N/A
Total Asset
109.31 B
54.77 B
N/A
1.27 B
1.32 B
117.21 B
305.61 B
6.95 B
1.77 B
N/A
Debt To Equity
159.7
239.0
N/A
1.33
0.21
54.4
N/A
2.38
2.31
N/A
Last Dividend Paid
2.19
0.67
0.32
0.16
N/A
3.61
N/A
11.1
N/A
N/A
Target Price
N/A
58.89
N/A
6.04
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
43.09
0.03
12.07
N/A
N/A
N/A
N/A
74.49
N/A
Market Capitalization
812.44 B
11.03 B
157.42 M
814.83 M
167.92 M
1.73 T
101.28 B
24.75 B
29.38 M
N/A
Price To Earning
50.79
78.94
98.94
4.69
312.5
102.83
N/A
0.19
N/A
N/A
Price To Earnings To Growth
2.41
0.7
N/A
N/A
N/A
4.98
1.89
N/A
N/A
N/A
Price To Sales
18.62
0.41
14.75
0.52
1.1
23.62
0.79
13.89
0.0385
N/A
Net Income
6.33 B
2.82 B
2.02 M
135.09 M
189.8 M
14.74 B
22.69 B
291.82 M
(136.28 M)
N/A
Earnings Per Share
15.61
1.38
1.08
0.5
1.21
2.15
1.44
1.56
-6.44
N/A
Shares Owned By Insiders
N/A
N/A
N/A
69.28
36.19
N/A
N/A
N/A
9.7
N/A
Revenue
46.16 B
26.8 B
10.67 M
1.27 B
266.95 M
80.19 B
232.31 B
1.61 B
1.05 B
N/A
Working Capital
N/A
N/A
N/A
N/A
(23 M)
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
29.36 B
435.34 M
N/A
186.95 M
55.87 M
9.82 B
N/A
448.96 M
1.84 M
N/A
Cash Per Share
17.95
1.36
N/A
1.37
8.71
3.92
N/A
74.36
1.35
N/A
Gross Profit
36.02 B
4.54 B
8.26 M
396.77 M
172.12 M
38.21 B
113.49 B
1.15 B
89.37 M
N/A
Day Typical Price
341.17
41.73
96.91
13.09
30.9
73.01
23.1
11.72
1.32
52.2
Accumulation Distribution
0.0925
79698.72
945.06
23507.5
N/A
551.56
0.0078
0.0093
0.0515
N/A
Market Facilitation Index
0.079
N/A
0.0
N/A
N/A
1.0E-4
0.18
0.11
0.07
N/A
Daily Balance Of Power
1.791139
0.9151
0.5328
0.6667
0.0
0.93
(3.28)
1.818182
(0.86)
(9,223,372,036,855)
Period Momentum Indicator
2.83
0.97
0.65
0.22
N/A
1.86
(0.59)
0.2
(0.06)
(0.15)
Rate Of Daily Change
1.01
1.02
1.01
1.02
1.0
1.03
0.98
1.02
0.96
1.0
Day Median Price
340.91
41.61
96.83
13.04
30.9
72.83
23.07
11.72
1.33
52.2
Price Action Indicator
2.2
0.84
0.57
0.27
N/A
1.46
(0.21)
0.12
(0.06)
(0.07)
Coefficient Of Variation
508.99
(500.68)
(1,135)
1958.29
(1,216)
1126.01
730.0
815.89
4294.5
8493.65
Mean Deviation
1.03
0.9947
0.5097
1.72
1.72
1.04
1.26
1.44
2.29
0.9498
Jensen Alpha
0.3679
(0.29)
(0.08)
0.0735
(0.34)
0.1413
0.2903
0.1783
0.1467
0.0017
Total Risk Alpha
0.1181
(0.45)
(0.17)
(0.18)
(0.75)
(0.07)
0.0041
(0.03)
(0.38)
(0.17)
Sortino Ratio
0.1203
N/A
N/A
(0.0004)
N/A
0.0128
0.1277
0.0639
(0.01)
(0.07)
Downside Variance
5.09
N/A
N/A
3.81
N/A
1.53
2.07
7.08
8.31
1.84
Standard Deviation
1.94
1.35
0.7227
2.13
3.5
1.41
2.14
2.28
3.46
1.34
Kurtosis
13.42
0.5791
2.49
(0.49)
7.08
2.55
19.3
3.44
5.41
2.08
Potential Upside
3.9
2.44
1.2
3.98
5.18
2.19
3.48
4.35
6.38
2.06
Treynor Ratio
11.56
(2.13)
(0.81)
0.3894
(0.68)
(0.44)
(4.13)
0.2939
(0.09)
0.1406
Maximum Drawdown
15.14
6.68
4.73
8.69
20.67
7.52
16.05
14.25
21.44
8.19
Variance
3.76
1.81
0.5223
4.54
12.24
1.99
4.59
5.2
12.01
1.8
Market Risk Adjusted Performance
11.57
(2.12)
(0.80)
0.3994
(0.67)
(0.43)
(4.12)
0.3039
(0.08)
0.1506
Risk Adjusted Performance
0.1559
(0.15)
(0.07)
0.0454
(0.05)
0.0723
0.1109
0.1001
0.0256
0.0133
Skewness
2.74
0.2453
0.5194
0.1715
(1.31)
0.8217
3.47
0.7898
1.6
0.415
Semi Deviation
0.6805
N/A
N/A
1.84
N/A
1.13
0.8725
1.49
2.45
1.27
Information Ratio
0.14
(0.28)
(0.24)
(0.0003)
(0.11)
0.0112
0.0859
0.0746
(0.01)
(0.07)
Value At Risk
(1.84)
(2.50)
(1.20)
(3.23)
(6.25)
(1.88)
(2.09)
(2.75)
(5.07)
(2.07)
Expected Short fall
(2.05)
N/A
N/A
(1.94)
N/A
(1.13)
(2.07)
(2.43)
(3.23)
(1.00)
Downside Deviation
2.26
N/A
N/A
1.95
N/A
1.24
1.44
2.66
2.88
1.36
Semi Variance
0.4631
N/A
N/A
3.38
N/A
1.27
0.7612
2.23
6.0
1.6

Bristol Myers Competition Performance Charts

Five steps to successful analysis of Bristol Myers Competition

Bristol Myers' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Bristol Myers Squibb in relation to its competition. Bristol Myers' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Bristol Myers in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Bristol Myers' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Bristol Myers Squibb, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Bristol Myers position

In addition to having Bristol Myers in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run ESG Investing Thematic Idea Now

ESG Investing
ESG Investing Theme
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Bristol Stock

When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
How To Invest In Bristol
Details
Is Bristol Stock a good investment?
Details
What is Bristol Myers' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Bristol Myers Correlation with its peers.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY